Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the deadliest malignancies worldwide due to the lack of effective treatments. Chemoprevention in high-risk patients is a promising, alternative strategy. In this study, pioglitazone was investigated for its ability to prevent hepatocarcinogenesis...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Gastrointest Surg
Päätekijät: Li, Shen, Ghoshal, Sarani, Sojoodi, Mozhdeh, Arora, Gunisha, Masia, Ricard, Erstad, Derek J., Lanuti, Michael, Hoshida, Yujin, Baumert, Thomas F., Tanabe, Kenneth K., Fuchs, Bryan C.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer US 2018
Aiheet:
2018 SSAT Plenary Presentation
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6328630/
https://ncbi.nlm.nih.gov/pubmed/30367397
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11605-018-4004-6
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia